Label extensions recommended by EMA/CHMP
As well as recommending approval of four novel medicines and three generic medicines at its September 2019 meetings, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced positive opinions for a number of label extensions, as follows:
- Merck KGaA(MRK: DE) and Pfizer's (NYSE: PFE) anti-PD-L1 antibody Bavencio (avelumab) in combination with the tyrosine kinase inhibitor Inlyta (axitinib) for the first-line treatment of adults with advanced renal cell carcinoma.
- GlaxoSmithKline's (LSE: GSK) intravenous formulation of Benlysta (belimumab as an add-on therapy in children aged five years and older with active, autoantibody-positive systemic lupus erythematous with a high degree of disease activity.
- Zentiva's Docetaxel Zentiva, previously known as Docetaxel Winthrop, in combination with androgen-deprivation therapy, with or without prednisone or prednisolone, for the treatment of patients with metastatic hormone-sensitive prostate cancer.
- Sanofi(Euronext: SAN) and Regeneron Pharmaceuticals' (NYSE: REGN) Dupixent (dupilumab) for the treatment of certain adults with severe chronic rhinosinusitis with nasal polyposis.
- Novartis' (NOVN: VX) anti-VEGF therapy Lucentis (ranibizumab)to include the treatment of proliferative diabetic retinopathy.
- Celltrion's biosimilar Remisima (infliximab)in a new subcutaneous formulation, delivered via prefilled pens or syringes, in combination with methotrexate, for use in adults with rheumatoid arthritis.
- Sanofi's Taxotere (docetaxel) to include use in combination with androgen-deprivation therapy, with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.
- Eli Lilly's (NYSE: KKY) GLP-1 receptor agonist Trulicity (dulaglutide)to include results from the REWIND cardiovascular outcomes trial, which achieved a significant 12% risk reduction in major adverse cardiovascular events, on the label.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze